Insight

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

Elisa Agostinetto/X

Jan 5, 2025, 18:21

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on LinkedIn:

“What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors (PPI) in breast cancer?

Can PPI use explain why the PALLAS trial was negative?

Now out in ESMO our analysis of PALLAS exploring this question.”

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Authors: E. Agostinetto, G. Pfeiler, D. Hlauschek, E.L. Mayer, M. Lambertini, E. de Azambuja, M. Bellet-Ezquerra, J.L. Meisel, G. Rubovszky, N. Zdenkowski, Y. Novik, M. Ruiz-Borrego, K.A. Gelmon, E.P. Mamounas, H. Iwata, D.R. Lu, L. Soelkner, C. Fesl, M. Gnant, A. DeMichele

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

A DeMichele Breast Cancer C. Fesl cancer D. Hlauschek D.R. Lu E. Agostinetto E. de Azambuja E.L. Mayer E.P. Mamounas Elisa Agostinetto G. Pfeiler G. Rubovszky H. Iwata J.L. Meisel K.A. Gelmon L. Soelkner M. Bellet-Ezquerra M. Gnant M. Lambertini M. Ruiz-Borrego N. Zdenkowski OncoDaily Oncology palbociclib PALLAS trial Y. Novik

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter